Girardet J P, Verlhac S, Liechtmaneger H, Fontaine J L
Arch Fr Pediatr. 1985 Oct;42(8):727-31.
The action, efficient dosage and tolerance of a pure vasodilator, dihydralazine, used for the treatment of severe heart failure were studied in 30 children aged 1 month to 14 years. All of them presented with heart failure from various causes, not controlled by the usual medical treatment. Dihydralazine was administered orally, without interrupting the digoxin-diuretic treatment, with a dose of 34 to 140 mg/m2/day given in 4 equal doses. Clinical efficacy was considered null in 12 cases, low in 12 cases and good in 6 cases, without relationship with the original heart defect. Five of the 6 good results were obtained with doses greater than or equal to 100 mg/m2/day. In the group of 16 children who were given doses greater than or equal to 100 mg/m2/day, a significant improvement of the ECG indexes of left ventricular performance was obtained: decrease in systolic left ventricular internal dimension (p less than 0.05 at day 5), increase of the shortening fraction (p less than 0.05 since day 1) and of velocity of shortening (p less than 0.01 since day 1), while the diastolic left ventricular internal dimension remained unchanged. The only transitory undesirable effects observed were headache, vomiting and/or rash in 9 cases.
对30名年龄在1个月至14岁的儿童进行了研究,以探讨用于治疗严重心力衰竭的纯血管扩张剂双肼屈嗪的作用、有效剂量和耐受性。所有患儿均因各种原因出现心力衰竭,常规治疗无法控制。双肼屈嗪口服给药,不中断地高辛 - 利尿剂治疗,剂量为34至140mg/m²/天,分4等份服用。临床疗效判定为无效12例,疗效低12例,疗效好6例,与原心脏缺陷无关。6例疗效好的患儿中有5例服用剂量大于或等于100mg/m²/天。在16名服用剂量大于或等于100mg/m²/天的儿童组中,左心室功能的心电图指标有显著改善:左心室收缩内径减小(第5天p<0.05),缩短分数增加(第1天起p<0.05)和缩短速度增加(第1天起p<0.01),而左心室舒张内径保持不变。仅观察到9例出现短暂的不良影响,表现为头痛、呕吐和/或皮疹。